卢比替定 lurbinectedin

Drug Class

Alkylating agent / RNA polymerase II inhibitor

Mechanism

Binds to guanine residues in the DNA minor groove, causing DNA double-strand breaks, inhibiting active transcription by stalling RNA polymerase II, and degrading the enzyme to induce tumor cell apoptosis.

Approved Indication

Treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.

What This Means For Patients

卢比替定 is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2020) — Sources
• NMPA — Approved (2024) — Sources

Pivotal Clinical Evidence

• Study B-005 — Trigo et al., Lancet Oncol 2020 (NCT02454972) — Sources

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf
• https://www.nmpa.gov.cn/